AZN.UK

10,198

-0.45%↓

GSK

1,383

+1.32%↑

INDV

839.5

-0.53%↓

AZN.UK

10,198

-0.45%↓

GSK

1,383

+1.32%↑

INDV

839.5

-0.53%↓

AZN.UK

10,198

-0.45%↓

GSK

1,383

+1.32%↑

INDV

839.5

-0.53%↓

AZN.UK

10,198

-0.45%↓

GSK

1,383

+1.32%↑

INDV

839.5

-0.53%↓

AZN.UK

10,198

-0.45%↓

GSK

1,383

+1.32%↑

INDV

839.5

-0.53%↓

Search

Haleon PLC

Ouvert

SecteurSoins de santé

405.6 1.37

Résumé

Variation du prix de l'action

24h

Actuel

Min

397.3

Max

405.7

Chiffres clés

By Trading Economics

Revenu

-254M

231M

Ventes

-21M

2.8B

P/E

Moyenne du Secteur

24.9

54.379

BPA

0.042

Rendement du dividende

1.66

Marge bénéficiaire

8.373

Employés

24,561

EBITDA

-317M

399M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+3.46% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.66%

2.55%

Prochains Résultats

31 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.9B

36B

Ouverture précédente

404.23

Clôture précédente

405.6

Sentiment de l'Actualité

By Acuity

50%

50%

195 / 382 Classement par Healthcare

Haleon PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 avr. 2025, 09:37 UTC

Acquisitions, Fusions, Rachats

Haleon Acquires Chinese JV in $264 Million Deal

19 mars 2025, 07:34 UTC

Acquisitions, Fusions, Rachats

Pfizer Sells Remaining 7.3% Haleon Shareholding for $3.25 Billion

18 mars 2025, 17:26 UTC

Acquisitions, Fusions, Rachats

Pfizer to Dispose of Remaining Shareholding in Haleon

30 avr. 2025, 08:33 UTC

Market Talk
Résultats

Haleon's Vitamins & Supplements Business Weakness in Focus Among Results -- Market Talk

30 avr. 2025, 06:09 UTC

Résultats

Haleon Expects Macroeconomic Environment to Remain Challenging, Uncertain

30 avr. 2025, 06:09 UTC

Résultats

Haleon Continues to Deliver Against Capital Allocation Priorities

30 avr. 2025, 06:08 UTC

Résultats

Analysts Saw Haleon 1Q Organic Revenue Growth at 5.1%

30 avr. 2025, 06:03 UTC

Résultats

Haleon Sees 2025 Adjusted Operating Profit Growth Ahead of Revenue Growth

30 avr. 2025, 06:03 UTC

Résultats

Haleon Sees 2025 Organic Revenue Growth of 4%-6%

30 avr. 2025, 06:03 UTC

Résultats

Haleon Backs 2025 View

30 avr. 2025, 06:03 UTC

Résultats

Haleon 1Q Rev GBP2.85B

30 avr. 2025, 06:01 UTC

Résultats

Haleon 1Q Organic Revenue Growth up 3.5%

29 avr. 2025, 19:47 UTC

Résultats

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

15 avr. 2025, 09:03 UTC

Acquisitions, Fusions, Rachats

Haleon: Deal Expected to Close Within Next Three Mos

15 avr. 2025, 09:03 UTC

Acquisitions, Fusions, Rachats

Haleon Has Bought Last 12% Interest for GBP200M

15 avr. 2025, 09:02 UTC

Acquisitions, Fusions, Rachats

Haleon Bought 33% interest in December 2024

15 avr. 2025, 09:02 UTC

Acquisitions, Fusions, Rachats

Haleon Buys 33% Interest in Tianjin TSKF Pharmaceutical from Tianjin Pharmaceutical Da Ren Tang

15 avr. 2025, 09:01 UTC

Acquisitions, Fusions, Rachats

Haleon Buys 33% Interest in Tianjin TSKF Pharmaceutical

18 mars 2025, 16:58 UTC

Acquisitions, Fusions, Rachats

Haleon Intends to Cancel Purchased Ordinary Shares

18 mars 2025, 16:57 UTC

Acquisitions, Fusions, Rachats

Citigroup: Off-Market Transaction Will Close at Same Time as or Following Settlement of Offering

18 mars 2025, 16:56 UTC

Acquisitions, Fusions, Rachats

Citigroup: Off-Market Purchase Worth Approx GBP170M in Ordinary Shares

18 mars 2025, 16:56 UTC

Acquisitions, Fusions, Rachats

Citigroup: Haleon Agreed to Carry out Off-Market Purchase From Pfizer

18 mars 2025, 16:52 UTC

Acquisitions, Fusions, Rachats

Haleon Takes Note of Announcement

18 mars 2025, 16:50 UTC

Acquisitions, Fusions, Rachats

Citigroup: Haleon Won't Receive Any Net Proceeds From Offering

18 mars 2025, 16:50 UTC

Acquisitions, Fusions, Rachats

Citigroup: This Is Subject to Customary Closing Conditions

18 mars 2025, 16:50 UTC

Acquisitions, Fusions, Rachats

Citigroup: Pfizer Will Receive All of Net Proceeds From Offering

18 mars 2025, 16:49 UTC

Acquisitions, Fusions, Rachats

Citigroup: Bookbuilding Period May Close at Any Time on Short Notice

18 mars 2025, 16:49 UTC

Acquisitions, Fusions, Rachats

Citigroup: Bookbuilding Period Will Commence Immediately

18 mars 2025, 16:49 UTC

Acquisitions, Fusions, Rachats

Citigroup: Price Per Sale Share to Be Determined Through Accelerated Bookbuilding Process

18 mars 2025, 16:48 UTC

Acquisitions, Fusions, Rachats

Citigroup: Pfizer Intends to Sell Ordinary Shares to Institutional Investors

Comparaison

Variation de prix

Haleon PLC prévision

Objectif de Prix

By TipRanks

3.46% hausse

Prévisions sur 12 Mois

Moyen 414.36 GBX  3.46%

Haut 475 GBX

Bas 315 GBX

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

6

Achat

4

Maintien

1

Vente

Sentiment

By Acuity

195 / 382Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Haleon PLC

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.